Literature DB >> 1833070

Ligand-sensitive binding of actin-binding protein to immunoglobulin G Fc receptor I (Fc gamma RI).

Y Ohta1, T P Stossel, J H Hartwig.   

Abstract

The high affinity receptor that binds the Fc domain of immunoglobulin G (IgG) subclasses 1 and 3 (Fc gamma RI) mediates important immune defense functions by inducing cell surface changes on human leukocytes. In this article, we document direct high affinity binding of Fc gamma RI to the actin filament cross-linking protein, actin-binding protein (ABP). In the absence of IgG, all Fc gamma RI molecules in undifferentiated cells of myeloid line U937 bound to ABP over a 9-fold range of Fc gamma RI expression induced by human IFN-gamma. Binding of IgG to U937 cells constitutively expressing Fc gamma RI or to COS cells genetically transfected to express Fc gamma RI rapidly decreased the avidity of Fc gamma RI for ABP. This finding suggests the existence of a pathway communicating a signal between a functional IgG receptor and intracellular components involved in the effector responses to Fc gamma RI-ligand interaction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1833070     DOI: 10.1016/0092-8674(91)90179-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  21 in total

1.  Monocyte-bound monoclonal antibodies inhibit the Fc gamma RI-mediated phagocytosis of sensitized red cells: the efficiency and mechanism of inhibition are determined by the nature of the antigen.

Authors:  S L Shepard; A G Hadley
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

2.  The small GTPase RalA targets filamin to induce filopodia.

Authors:  Y Ohta; N Suzuki; S Nakamura; J H Hartwig; T P Stossel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

3.  Serine phosphorylation of FcγRI cytoplasmic domain directs lipid raft localization and interaction with protein 4.1G.

Authors:  Andrew W Gibson; Xinrui Li; Jianming Wu; Julie G Baskin; Chander Raman; Jeffrey C Edberg; Robert P Kimberly
Journal:  J Leukoc Biol       Date:  2011-10-14       Impact factor: 4.962

4.  Requirements for different components of the host cell cytoskeleton distinguish ecotropic murine leukemia virus entry via endocytosis from entry via surface fusion.

Authors:  K Kizhatil; L M Albritton
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A.

Authors:  R Lin; K Karpa; N Kabbani; P Goldman-Rakic; R Levenson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

6.  Signal transduction during Legionella pneumophila entry into human monocytes.

Authors:  P Y Coxon; J T Summersgill; J A Ramirez; R D Miller
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

7.  The functional activity of human monocytes passively sensitized with monoclonal anti-D suggests a novel role for Fc gamma RI in the immune destruction of blood cells.

Authors:  H L Griffiths; B M Kumpel; C J Elson; A G Hadley
Journal:  Immunology       Date:  1994-11       Impact factor: 7.397

8.  Association of the high-affinity receptor for IgG (Fc gamma RI) with the gamma subunit of the IgE receptor.

Authors:  L K Ernst; A M Duchemin; C L Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

9.  Cloning from the thyroid of a protein related to actin binding protein that is recognized by Graves disease immunoglobulins.

Authors:  P J Leedman; B Faulkner-Jones; D S Cram; P J Harrison; J West; E O'Brien; R Simpson; R L Coppel; L C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

10.  ASB2 targets filamins A and B to proteasomal degradation.

Authors:  Mélina L Heuzé; Isabelle Lamsoul; Massimiliano Baldassarre; Yatish Lad; Sophie Lévêque; Ziba Razinia; Christel Moog-Lutz; David A Calderwood; Pierre G Lutz
Journal:  Blood       Date:  2008-09-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.